藥廠

科學

EP237-一劑一億元，貴嗎?了解孤兒藥的價值、開發流程和商業模式

Play Episode Pause Episode

1x

00:00 /

RSS Feed

Share

Link

Embed

<blockquote class="wp-embedded-content" data-secret="g6zjjpPh6Q"><a href="https://podcast.biomeder.com/episodes/aadc-deficiency-orphan-drug-price-development-business-model/">EP237-一劑一億元，貴嗎?了解孤兒藥的價值、開發流程和商業模式</a></blockquote><iframe sandbox="allow-scripts" security="restricted" src="https://podcast.biomeder.com/episodes/aadc-deficiency-orphan-drug-price-development-business-model/embed/#?secret=g6zjjpPh6Q" width="500" height="350" title="EP237-一劑一億元，貴嗎?了解孤兒藥的價值、開發流程和商業模式 &#8212; 生醫人生旅歷" data-secret="g6zjjpPh6Q" frameborder="0" marginwidth="0" marginheight="0" scrolling="no" class="wp-embedded-content"></iframe><script> /*! This file is auto-generated */ !function(d,l){"use strict";l.querySelector&&d.addEventListener&&"undefined"!=typeof URL&&(d.wp=d.wp||{},d.wp.receiveEmbedMessage||(d.wp.receiveEmbedMessage=function(e){var t=e.data;if((t||t.secret||t.message||t.value)&&!/[^a-zA-Z0-9]/.test(t.secret)){for(var s,r,n,a=l.querySelectorAll('iframe[data-secret="'+t.secret+'"]'),o=l.querySelectorAll('blockquote[data-secret="'+t.secret+'"]'),c=new RegExp("^https?:$","i"),i=0;i<o.length;i++)o[i].style.display="none";for(i=0;i<a.length;i++)s=a[i],e.source===s.contentWindow&&(s.removeAttribute("style"),"height"===t.message?(1e3<(r=parseInt(t.value,10))?r=1e3:~~r<200&&(r=200),s.height=r):"link"===t.message&&(r=new URL(s.getAttribute("src")),n=new URL(t.value),c.test(n.protocol))&&n.host===r.host&&l.activeElement===s&&(d.top.location.href=t.value))}},d.addEventListener("message",d.wp.receiveEmbedMessage,!1),l.addEventListener("DOMContentLoaded",function(){for(var e,t,s=l.querySelectorAll("iframe.wp-embedded-content"),r=0;r<s.length;r++)(t=(e=s[r]).getAttribute("data-secret"))||(t=Math.random().toString(36).substring(2,12),e.src+="#?secret="+t,e.setAttribute("data-secret",t)),e.contentWindow.postMessage({message:"ready",secret:t},"*")},!1)))}(window,document); //# sourceURL=https://podcast.biomeder.com/wp-includes/js/wp-embed.min.js </script>

日前台灣衛福部健保署公布對AADC 缺乏症的基因治療新藥Upstaza納入健保給付。2025年 12 月1日起，針對 18 個月以上、未滿 6 歲的「嚴重表現型」AADC 缺乏症病童，提供這款基因治療新藥的暫時性給付。原則上會每 2 至 3 年進行一次再評估。這件事情在社會上出現不同的聲音，有人反對也有人支持。